Our REACH offerings will help you develop your business strategy for REACH and act as “only representative” for importers into Europe
ECHA publishes new data sharing regulation under REACH affecting process and costs of data to be shared between the Lead Registrant and Co-Registrant. The new regulation will come into force on 26th January. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0009&from=EN
ECHA Biocides Committee has approved 14 dossiers of active substance/product type combinations. This brings the number of opinions on approvals adopted up to 50. http://echa.europa.eu/documents/10162/21774240/annex_bpc_13_NA.pdf
This follows the European Court of Justice landmark ruling of 10th September 2015 that articles incorporated as components of a complex product must be notified to ECHA if containing Substance of Very High Concern at above 1%. The case relates
The 2018 deadline is for substances in the lowest tonnage band: 1-100t. A first step of for companies to decide which substances they will register and join the specific SIEF (Substance Information Exchange Forum). Some 70,000 registrations are expected to
ECHA has prepared a proposal to update the Community rolling action plan (CoRAP) for 2016-2018. The Member States are planning to evaluate 138 substances, out of which 53 are newly selected. The final plan will be adopted in March 2016.
Today, Linmark Consulting launched the new webpage for Organoclays REACH Consortium Click here for further information
Today, Linmark Consulting launches the new webpage for Polyamides (PAEA) REACH Consortium Click here for further information
The European regulatory authority ECHA released its 3-yearly regulatory science strategy setting out its aims for priority areas, to aid scientific cooperation and consensus, communicate R&D needs and ultimately help improve risk assessment methods. It wishes to act as a
The US EPA has invited comments on three draft test guidelines for its Endocrine Disruptor Screening Program (EDSP). The tests are part of the program’s tier 2, which will be used for substances that show endocrine-disrupting properties in tier 1.